Geneva, March 20 -- International Clinical Trials Registry received information related to the study (NCT07444619) titled 'A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue Sarcomas' on Feb. 26.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Soft Tissue Sarcomas
Intervention:
Drug: Pazopanib
Drug: Trabectedin
Drug: Ipilimumab
Recruitment Status: Not recruiting
Phase: Phase 1
Date of First Enrollment: August 31, 2026
Target Sample Size: 18
Countries...